000136301 001__ 136301
000136301 005__ 20240731105612.0
000136301 0247_ $$2doi$$a10.1016/j.heliyon.2024.e33684
000136301 0248_ $$2sideral$$a139276
000136301 037__ $$aART-2024-139276
000136301 041__ $$aeng
000136301 100__ $$aZapata-García, María
000136301 245__ $$aImpact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer
000136301 260__ $$c2024
000136301 5060_ $$aAccess copy available to the general public$$fUnrestricted
000136301 5203_ $$aLung cancer is a leading cause of morbidity and mortality globally, with its high mortality rate attributed mainly to non-small cell lung cancer (NSCLC). Although immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized its treatment, patient response is highly variable and lacking predictive markers. We conducted a prospective study on 55 patients with NSCLC undergoing ICI therapy to identify predictive markers of both response and immune-related adverse events (IrAEs) in the airway microbiota. We also analyzed the clinical evolution and overall survival (OS) with respect to treatments that affect the integrity of the microbiota, such as antibiotics and corticosteroids. Our results demonstrated that respiratory microbiota differ significantly in ICI responders: they have higher alpha diversity values and lower abundance of the Firmicutes phylum and the Streptococcus genus. Employing a logistic regression model, the abundance of Gemella was the major predictor of non-ICI response, whereas Lachnoanaerobaculum was the best predictor of a positive response to ICI. The most relevant results were that antibiotic consumption is linked to a lower ICI response, and the use of corticosteroids correlated with poorer overall survival. Whereas previous studies have focused on gut microbiota, our findings highlight the importance of the respiratory microbiota in predicting the treatment response. Future research should explore microbiota modulation strategies to enhance immunotherapy outcomes. Understanding the impact of antibiotics, corticosteroids, and microbiota on NSCLC immunotherapy will help personalize treatment and improve patient outcomes
000136301 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000136301 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000136301 700__ $$aMoratiel-Pellitero, Alba
000136301 700__ $$aIsla, Dolores
000136301 700__ $$aGálvez, Eva$$uUniversidad de Zaragoza
000136301 700__ $$aGascón-Ruiz, Marta
000136301 700__ $$aSesma, Andrea
000136301 700__ $$aBarbero, Raquel
000136301 700__ $$aGaleano, Javier
000136301 700__ $$adel Campo, Rosa
000136301 700__ $$aOcáriz, Maitane
000136301 700__ $$aQuílez, Elisa
000136301 700__ $$aCruellas, Mara
000136301 700__ $$aRamírez-Labrada, Ariel
000136301 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, Julián$$uUniversidad de Zaragoza
000136301 700__ $$aMartínez-Lostao, Luis
000136301 700__ $$aDomingo, María Pilar
000136301 700__ $$aEsteban, Patricia
000136301 700__ $$0(orcid)0000-0003-3387-0558$$aTorres-Ramón, Irene
000136301 700__ $$aYubero, Alfonso
000136301 700__ $$0(orcid)0000-0002-9600-8116$$aPaño, José Ramón$$uUniversidad de Zaragoza
000136301 700__ $$aLastra, Rodrigo
000136301 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000136301 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000136301 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000136301 773__ $$g10, 13 (2024), e33684 [13 pp.]$$pHeliyon$$tHeliyon$$x2405-8440
000136301 8564_ $$s4955506$$uhttps://zaguan.unizar.es/record/136301/files/texto_completo.pdf$$yVersión publicada
000136301 8564_ $$s1850174$$uhttps://zaguan.unizar.es/record/136301/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000136301 909CO $$ooai:zaguan.unizar.es:136301$$particulos$$pdriver
000136301 951__ $$a2024-07-31-09:22:32
000136301 980__ $$aARTICLE